Tralokinumab Biosimilar - Research Grade

Human

IL-13

>1mg/ml

Human IgG4 S228P Kappa

Lebrikizumab Biosimilar - Research Grade (ICH5058), Abrezekimab Biosimilar - Research Grade (ICH5324), Anrukinzumab Biosimilar - Research Grade (ICH5347), Cendakimab Biosimilar - Research Grade (ICH5432), Dectrekumab Biosimilar - Research Grade (ICH5470)

https://www.imgt.org/mAb-DB/

ICH3002

P35225

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-IL-13 antibody tralokinumab, supplied strictly for research use only. It is built around the same molecular target, human interleukin-13 (IL-13, UniProt P35225), and is expressed as a full-length human IgG4 (S228P-stabilised) kappa immunoglobulin so that its binding behaviour and Fc characteristics mirror the originator format. It is not the clinical drug and is not intended for human or veterinary use. The analog is useful for research because it provides a well-defined, target-specific reagent for interrogating IL-13 biology in vitro and in cell-based systems: it can serve as a neutralising tool to block IL-13 signalling, as an isotype-matched positive control in binding and blocking assays, as a benchmark reference for characterising other anti-IL-13 candidates, and as a starting scaffold for ADC or engineering workflows. It is offered at research-grade low endotoxin (<1 EU/mg), with ultra-low-endotoxin (<0.5 EU/mg) and in-vivo-standard formats available, and in bulk milligram-to-gram quantities to support screening, assay development, and preclinical model work. Interleukin-13 (IL-13) is a type 2 (Th2) cytokine central to allergic inflammation, produced by activated T cells, mast cells, basophils, eosinophils, and innate lymphoid cells. It signals through a receptor system it shares in part with IL-4: IL-13 binds the IL-13Ra1 chain, which pairs with IL-4Ra to form the type II receptor and drive STAT6-dependent transcription. A second receptor, IL-13Ra2, binds IL-13 with high affinity and largely acts as a decoy/regulatory sink. Downstream effects include IgE class switching, goblet-cell hyperplasia and mucus production, smooth-muscle hyperresponsiveness, eosinophil recruitment, and fibrosis. IL-13 is a validated driver of asthma and atopic dermatitis, which is why blocking it is therapeutically important. Notably, tralokinumab binds IL-13 in a way that prevents its interaction with both IL-13Ra1 and IL-13Ra2, distinguishing its mechanism from receptor-chain-directed approaches.

Interleukin-13, NC30

Detects human IL-13. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tralokinumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.